Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Joseph Saseen

Concepts (455)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
28
2025
445
5.350
 Why?
Atherosclerosis
9
2025
415
3.510
 Why?
Hypertension
23
2024
1295
2.780
 Why?
Cardiovascular Diseases
22
2025
2111
2.740
 Why?
Cholesterol, LDL
14
2025
365
2.730
 Why?
Antihypertensive Agents
14
2024
494
2.720
 Why?
Pharmacists
17
2023
265
2.710
 Why?
Hypercholesterolemia
9
2025
106
1.930
 Why?
Students, Pharmacy
7
2018
97
1.820
 Why?
Hypolipidemic Agents
8
2021
91
1.460
 Why?
Educational Measurement
5
2018
289
1.430
 Why?
Practice Patterns, Physicians'
6
2025
1313
1.410
 Why?
Blood Pressure
12
2024
1786
1.390
 Why?
Professional Role
7
2020
167
1.390
 Why?
Education, Pharmacy
7
2018
120
1.380
 Why?
Medication Therapy Management
5
2018
76
1.220
 Why?
Practice Guidelines as Topic
13
2020
1587
1.220
 Why?
Anticholesteremic Agents
7
2021
153
1.190
 Why?
Dyslipidemias
7
2016
176
1.170
 Why?
Lipids
3
2022
672
1.090
 Why?
Cholesterol
5
2020
410
1.080
 Why?
Ambulatory Care
9
2018
546
1.070
 Why?
Calcium Channel Blockers
7
2015
167
1.050
 Why?
Managed Care Programs
4
2014
135
1.040
 Why?
Gout
4
2025
37
0.960
 Why?
Humans
136
2025
137585
0.960
 Why?
Societies, Pharmaceutical
7
2017
21
0.960
 Why?
Renal Insufficiency, Chronic
2
2025
617
0.920
 Why?
Chlorthalidone
2
2014
5
0.920
 Why?
Hydrochlorothiazide
2
2014
9
0.920
 Why?
Retrospective Studies
38
2025
15657
0.910
 Why?
Pharmaceutical Services
5
2020
83
0.900
 Why?
Arthritis, Gouty
2
2016
15
0.900
 Why?
Anti-Inflammatory Agents, Non-Steroidal
5
2018
350
0.840
 Why?
Adrenergic beta-Antagonists
4
2014
323
0.820
 Why?
Education, Pharmacy, Graduate
4
2017
17
0.810
 Why?
Pharmacy Residencies
3
2018
11
0.810
 Why?
Aged
41
2025
23961
0.810
 Why?
Urinary Tract Infections
2
2023
188
0.810
 Why?
American Heart Association
4
2020
306
0.790
 Why?
Diabetes Mellitus
4
2023
1040
0.770
 Why?
Primary Health Care
10
2025
1738
0.750
 Why?
Clinical Competence
4
2018
1118
0.740
 Why?
Middle Aged
43
2025
33479
0.730
 Why?
Blood Glucose
4
2017
2186
0.730
 Why?
Diuretics
4
2014
74
0.720
 Why?
Dicarboxylic Acids
1
2021
9
0.720
 Why?
Coronary Artery Disease
3
2021
698
0.710
 Why?
Serotonin 5-HT1 Receptor Agonists
1
2020
4
0.710
 Why?
Preceptorship
2
2018
66
0.700
 Why?
Angiotensin-Converting Enzyme Inhibitors
5
2011
201
0.700
 Why?
Evidence-Based Medicine
14
2018
740
0.700
 Why?
Drug Prescriptions
2
2020
245
0.700
 Why?
Teaching
3
2018
224
0.670
 Why?
Gout Suppressants
3
2025
20
0.670
 Why?
Diabetes Mellitus, Type 2
7
2022
2531
0.670
 Why?
Hypoglycemic Agents
4
2014
1291
0.650
 Why?
Muscular Diseases
2
2015
114
0.640
 Why?
Proton Pump Inhibitors
2
2024
109
0.620
 Why?
Migraine Disorders
1
2020
102
0.620
 Why?
Aged, 80 and over
17
2025
7635
0.620
 Why?
Health Benefit Plans, Employee
2
2017
25
0.610
 Why?
Emergency Service, Hospital
2
2020
2069
0.600
 Why?
Drug Therapy
2
2017
85
0.590
 Why?
Acetaminophen
3
2007
268
0.570
 Why?
Fatty Acids
1
2021
443
0.560
 Why?
Insurance Coverage
2
2011
230
0.560
 Why?
Female
54
2025
73304
0.560
 Why?
Male
49
2025
67762
0.550
 Why?
Simvastatin
3
2015
61
0.550
 Why?
Primary Prevention
4
2025
196
0.540
 Why?
Faculty, Pharmacy
1
2017
20
0.530
 Why?
Schools, Pharmacy
1
2017
47
0.530
 Why?
Research
2
2017
451
0.520
 Why?
Adult
33
2025
37929
0.510
 Why?
HIV
1
2017
234
0.500
 Why?
Population Health
1
2017
47
0.500
 Why?
Cardiology
4
2018
274
0.490
 Why?
Antipsychotic Agents
1
2017
194
0.480
 Why?
Hyperlipidemias
5
2018
120
0.480
 Why?
Perception
1
2018
359
0.480
 Why?
Anti-Retroviral Agents
1
2017
233
0.480
 Why?
Monitoring, Physiologic
1
2017
275
0.470
 Why?
Heart Failure
3
2023
2236
0.470
 Why?
Faculty, Medical
1
2017
283
0.440
 Why?
Angiotensin II Type 1 Receptor Blockers
2
2013
38
0.440
 Why?
Poverty
2
2008
521
0.440
 Why?
Treatment Outcome
17
2024
10811
0.440
 Why?
United States
24
2025
14841
0.440
 Why?
Program Evaluation
3
2017
898
0.430
 Why?
Gastrointestinal Hemorrhage
2
2024
132
0.430
 Why?
Analgesics, Non-Narcotic
2
2007
125
0.430
 Why?
Aspirin
3
2024
387
0.420
 Why?
Risk Factors
18
2025
10388
0.420
 Why?
Tetrazoles
1
2013
41
0.420
 Why?
Drug Therapy, Combination
12
2020
1066
0.420
 Why?
Ezetimibe
4
2021
24
0.410
 Why?
Self Report
1
2017
827
0.410
 Why?
Guideline Adherence
4
2025
556
0.400
 Why?
Xanthine Oxidase
3
2025
81
0.400
 Why?
Gemfibrozil
3
2016
11
0.400
 Why?
Osteoarthritis
2
2006
185
0.400
 Why?
Anti-Arrhythmia Agents
2
2003
114
0.390
 Why?
Glomerular Filtration Rate
3
2025
746
0.390
 Why?
Curriculum
6
2018
992
0.390
 Why?
Adrenal Cortex Hormones
2
2016
565
0.390
 Why?
Analgesics, Opioid
1
2020
1000
0.390
 Why?
Venoms
1
2012
29
0.390
 Why?
Imidazoles
1
2013
238
0.380
 Why?
Colorado
13
2024
4565
0.380
 Why?
Text Messaging
2
2025
157
0.370
 Why?
Health Expenditures
5
2017
189
0.370
 Why?
Lipoprotein(a)
2
2022
67
0.360
 Why?
Problem-Based Learning
3
2017
92
0.360
 Why?
Health Resources
1
2012
120
0.360
 Why?
Kidney
1
2019
1468
0.350
 Why?
Electronic Health Records
5
2018
1069
0.350
 Why?
Medicare Part D
1
2011
25
0.340
 Why?
Risk Assessment
11
2022
3457
0.330
 Why?
Insurance Claim Review
3
2017
64
0.320
 Why?
Arthritis, Rheumatoid
3
2009
1167
0.320
 Why?
Patient Care Team
5
2024
631
0.320
 Why?
Young Adult
10
2025
13209
0.320
 Why?
Consensus
5
2025
683
0.320
 Why?
Azetidines
2
2008
43
0.320
 Why?
Societies, Medical
5
2025
820
0.310
 Why?
Rosuvastatin Calcium
2
2025
22
0.310
 Why?
Drug Interactions
4
2022
410
0.300
 Why?
Antirheumatic Agents
2
2009
293
0.290
 Why?
Clinical Trials as Topic
8
2017
1050
0.290
 Why?
Antibodies, Monoclonal
4
2020
1430
0.290
 Why?
Community Health Centers
2
2018
60
0.290
 Why?
Age Factors
5
2017
3295
0.280
 Why?
Drug Costs
2
2006
106
0.280
 Why?
Cohort Studies
10
2020
5742
0.270
 Why?
Venous Thromboembolism
2
2022
316
0.270
 Why?
HIV Infections
2
2023
2836
0.270
 Why?
Platelet Aggregation Inhibitors
2
2024
463
0.260
 Why?
Verapamil
2
1997
41
0.260
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
47
0.260
 Why?
Kidney Failure, Chronic
2
2010
570
0.260
 Why?
Tablets
1
2006
40
0.260
 Why?
Family Practice
4
2015
464
0.260
 Why?
Liver Diseases, Alcoholic
1
2007
93
0.260
 Why?
Certification
2
2006
113
0.260
 Why?
Weight Loss
3
2012
787
0.260
 Why?
Renal Dialysis
1
2010
435
0.250
 Why?
Peptides
1
2012
985
0.250
 Why?
Cyclooxygenase 2 Inhibitors
1
2006
21
0.250
 Why?
Drug Compounding
1
2006
101
0.250
 Why?
Reminder Systems
2
2025
169
0.250
 Why?
Randomized Controlled Trials as Topic
7
2007
1477
0.250
 Why?
Lipoproteins
1
2007
168
0.240
 Why?
Chemical and Drug Induced Liver Injury
2
2007
137
0.240
 Why?
Sodium Chloride, Dietary
1
2006
36
0.240
 Why?
Patient Care
3
2017
111
0.240
 Why?
Insurance, Health
4
2015
283
0.240
 Why?
Enzyme Inhibitors
2
2025
840
0.240
 Why?
Benzothiadiazines
1
2005
3
0.240
 Why?
Ambulatory Care Facilities
2
2017
232
0.240
 Why?
Sodium Chloride Symporter Inhibitors
1
2005
8
0.240
 Why?
Blood Pressure Determination
3
2018
157
0.230
 Why?
Brain Ischemia
1
2008
338
0.230
 Why?
Drug Labeling
3
2015
39
0.230
 Why?
Quality Assurance, Health Care
1
2006
322
0.220
 Why?
Bronchiolitis, Viral
1
2004
12
0.220
 Why?
Adolescent
8
2025
21513
0.220
 Why?
Patient-Centered Care
3
2015
530
0.210
 Why?
Off-Label Use
2
2015
52
0.210
 Why?
Epinephrine
1
2004
139
0.210
 Why?
Contraceptive Agents
1
2004
66
0.210
 Why?
Progesterone Congeners
1
2003
16
0.200
 Why?
Medroxyprogesterone
1
2003
11
0.200
 Why?
Cardiovascular Agents
1
2025
159
0.200
 Why?
Life Style
1
2006
490
0.200
 Why?
Hormone Replacement Therapy
1
2004
100
0.200
 Why?
Incidence
3
2023
2804
0.200
 Why?
Quality Indicators, Health Care
1
2005
307
0.200
 Why?
Secondary Prevention
3
2024
233
0.200
 Why?
Estrogens, Conjugated (USP)
1
2003
49
0.200
 Why?
Faculty
2
2018
147
0.200
 Why?
C-Reactive Protein
1
2005
410
0.190
 Why?
Tumor Necrosis Factor-alpha
1
2007
1242
0.190
 Why?
Heart Conduction System
1
2003
99
0.190
 Why?
Bronchodilator Agents
1
2004
252
0.190
 Why?
Program Development
2
2017
364
0.190
 Why?
Death, Sudden, Cardiac
1
2003
185
0.190
 Why?
Contraception
1
2004
161
0.190
 Why?
Estrogen Replacement Therapy
1
2003
146
0.180
 Why?
Attitude to Health
1
2005
439
0.180
 Why?
Antiphospholipid Syndrome
1
2021
34
0.180
 Why?
Atenolol
2
2014
7
0.180
 Why?
Communicable Diseases
1
2023
159
0.180
 Why?
Vasodilator Agents
1
2003
331
0.170
 Why?
Medication Adherence
1
2025
467
0.170
 Why?
Pre-Exposure Prophylaxis
1
2023
213
0.170
 Why?
Uric Acid
2
2025
163
0.170
 Why?
Drug Tolerance
1
2021
105
0.170
 Why?
Transition to Adult Care
1
2022
91
0.170
 Why?
Public Health Administration
1
2021
76
0.170
 Why?
Costs and Cost Analysis
3
2014
213
0.170
 Why?
Diabetic Nephropathies
1
2004
294
0.170
 Why?
Dipyrone
1
1999
1
0.160
 Why?
Methenamine
1
2019
5
0.160
 Why?
Dose-Response Relationship, Drug
4
2014
2057
0.160
 Why?
Appetite Stimulants
1
1999
2
0.160
 Why?
Cross-Sectional Studies
4
2025
5472
0.160
 Why?
Anti-Infective Agents, Urinary
1
2019
14
0.160
 Why?
HIV Wasting Syndrome
1
1999
4
0.160
 Why?
Anabolic Agents
1
1999
12
0.160
 Why?
Stroke
1
2008
1120
0.160
 Why?
Nifedipine
2
1996
29
0.160
 Why?
Diltiazem
2
1996
29
0.160
 Why?
Pharmacy Service, Hospital
2
2013
90
0.160
 Why?
Drug and Narcotic Control
1
1999
28
0.160
 Why?
Proprotein Convertase 9
1
2019
73
0.150
 Why?
Internship, Nonmedical
3
2011
14
0.150
 Why?
Patient Education as Topic
3
2024
766
0.150
 Why?
Heart Rate
1
2003
822
0.150
 Why?
Protons
1
2019
89
0.150
 Why?
Federal Government
1
2018
28
0.150
 Why?
Guidelines as Topic
2
2019
275
0.150
 Why?
Atrial Fibrillation
1
2003
388
0.150
 Why?
Training Support
1
2018
35
0.140
 Why?
Health Services
2
2009
107
0.140
 Why?
Acquired Immunodeficiency Syndrome
1
1999
230
0.140
 Why?
Risk
2
2017
912
0.140
 Why?
Thrombosis
1
2021
371
0.140
 Why?
Medically Underserved Area
1
2018
85
0.140
 Why?
Peripheral Arterial Disease
1
2024
475
0.140
 Why?
Severity of Illness Index
3
2019
2828
0.130
 Why?
Models, Econometric
1
2017
34
0.130
 Why?
Quality of Health Care
2
2017
642
0.130
 Why?
Vulnerable Populations
1
2018
163
0.130
 Why?
Anticoagulants
4
2022
664
0.130
 Why?
Colchicine
1
2016
24
0.130
 Why?
Anti-HIV Agents
1
2023
778
0.130
 Why?
Warfarin
3
2021
154
0.130
 Why?
United States Food and Drug Administration
2
2015
208
0.130
 Why?
Protease Inhibitors
1
2017
107
0.130
 Why?
Hyperuricemia
1
2016
44
0.130
 Why?
Point-of-Care Systems
1
2018
167
0.130
 Why?
Chronic Disease
3
2013
1793
0.120
 Why?
Alcoholism
1
2003
807
0.120
 Why?
Comorbidity
4
2016
1622
0.120
 Why?
Amlodipine
1
2015
9
0.120
 Why?
Pharmacovigilance
1
2015
23
0.120
 Why?
Education, Medical, Undergraduate
1
2017
188
0.120
 Why?
Surveys and Questionnaires
2
2018
5778
0.110
 Why?
Systole
1
2014
189
0.110
 Why?
Ethanolamines
1
2014
17
0.110
 Why?
Nebivolol
1
2014
9
0.110
 Why?
Liver
1
2003
1943
0.110
 Why?
Benzopyrans
1
2014
26
0.110
 Why?
Metoprolol
1
2014
40
0.110
 Why?
Exercise
1
2006
2057
0.110
 Why?
Risk Reduction Behavior
3
2022
220
0.110
 Why?
Geriatrics
2
2025
98
0.110
 Why?
Carbazoles
1
2014
83
0.110
 Why?
Follow-Up Studies
3
2016
5131
0.110
 Why?
Losartan
1
2013
14
0.110
 Why?
Valsartan
1
2013
29
0.110
 Why?
Propanolamines
1
2014
96
0.100
 Why?
Drug Substitution
1
2013
54
0.100
 Why?
Valine
1
2013
82
0.100
 Why?
Biphenyl Compounds
1
2013
63
0.100
 Why?
Medicaid
1
2017
435
0.100
 Why?
Antidepressive Agents, Second-Generation
2
2004
45
0.100
 Why?
Fibric Acids
1
2012
3
0.100
 Why?
Contraindications
1
2012
90
0.100
 Why?
Patient Acceptance of Health Care
2
2012
806
0.100
 Why?
Socioeconomic Factors
1
2017
1289
0.100
 Why?
Drug Combinations
2
2016
343
0.100
 Why?
Telemedicine
1
2021
862
0.090
 Why?
Biomarkers
5
2018
4149
0.090
 Why?
Internship and Residency
2
2017
1147
0.090
 Why?
Reproducibility of Results
3
2005
3284
0.090
 Why?
Decision Support Systems, Clinical
1
2015
226
0.090
 Why?
Age Distribution
1
2012
392
0.090
 Why?
Double-Blind Method
4
2003
1993
0.090
 Why?
Vascular Endothelial Growth Factor A
1
2014
545
0.090
 Why?
Annual Reports as Topic
1
2010
3
0.090
 Why?
Professional Staff Committees
1
2010
13
0.090
 Why?
Financing, Personal
1
2011
26
0.090
 Why?
Sex Factors
1
2017
2071
0.090
 Why?
Insurance Benefits
1
2010
11
0.090
 Why?
Insurance, Pharmaceutical Services
1
2010
22
0.090
 Why?
Interpersonal Relations
1
2014
397
0.090
 Why?
Pharmacy
1
2010
32
0.080
 Why?
Acute Kidney Injury
1
2018
815
0.080
 Why?
Creatinine
1
2012
499
0.080
 Why?
Analysis of Variance
1
2012
1316
0.080
 Why?
Drug Utilization Review
2
2006
57
0.080
 Why?
Nutrition Surveys
2
2021
266
0.080
 Why?
Prescription Drugs
1
2010
109
0.080
 Why?
Hypoglycemia
1
2014
445
0.080
 Why?
Hyperlipoproteinemia Type II
2
2019
35
0.080
 Why?
Dipyridamole
1
2008
28
0.080
 Why?
Ezetimibe, Simvastatin Drug Combination
1
2008
1
0.070
 Why?
Fluorobenzenes
1
2008
16
0.070
 Why?
Ticlopidine
1
2008
52
0.070
 Why?
Drug Administration Schedule
2
2007
786
0.070
 Why?
Patient Compliance
3
2008
581
0.070
 Why?
Ischemic Attack, Transient
1
2008
65
0.070
 Why?
Abatacept
1
2007
53
0.070
 Why?
Health Knowledge, Attitudes, Practice
1
2016
1329
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2007
86
0.070
 Why?
Dipeptidyl Peptidase 4
1
2007
13
0.070
 Why?
Adamantane
1
2007
18
0.070
 Why?
Proportional Hazards Models
1
2011
1266
0.070
 Why?
Timolol
1
2007
14
0.070
 Why?
Hemorrhage
2
2022
722
0.070
 Why?
Contraception, Postcoital
1
2007
6
0.070
 Why?
Propranolol
1
2007
50
0.070
 Why?
Accreditation
1
2007
83
0.070
 Why?
Pyrrolidines
1
2007
79
0.070
 Why?
Community Pharmacy Services
1
2007
45
0.070
 Why?
Levonorgestrel
1
2007
38
0.070
 Why?
Rituximab
1
2007
176
0.070
 Why?
Specialty Boards
1
2006
36
0.060
 Why?
Nitriles
1
2007
172
0.060
 Why?
Immunoconjugates
1
2007
114
0.060
 Why?
Anti-Ulcer Agents
1
2006
16
0.060
 Why?
Cost Savings
1
2006
84
0.060
 Why?
Medication Errors
1
2006
95
0.060
 Why?
Safety Management
1
2006
124
0.060
 Why?
Delivery of Health Care
3
2022
951
0.060
 Why?
Case Management
1
2005
66
0.060
 Why?
Efficiency, Organizational
1
2005
140
0.060
 Why?
Pharmaceutical Preparations
1
2006
179
0.060
 Why?
Pyrimidines
1
2008
470
0.060
 Why?
Benchmarking
1
2005
186
0.050
 Why?
Sulfonamides
1
2008
513
0.050
 Why?
Nephrology
1
2005
61
0.050
 Why?
Professional-Patient Relations
1
2005
145
0.050
 Why?
Rhabdomyolysis
1
2003
21
0.050
 Why?
Coronary Disease
2
2003
385
0.050
 Why?
Amiodarone
1
2003
26
0.050
 Why?
Albuterol
1
2004
110
0.050
 Why?
Child, Preschool
2
2017
11074
0.050
 Why?
Longitudinal Studies
1
2011
2844
0.050
 Why?
Medicare
1
2009
773
0.050
 Why?
Meta-Analysis as Topic
1
2004
186
0.050
 Why?
Disease Susceptibility
1
2005
347
0.050
 Why?
Liver Function Tests
1
2003
114
0.050
 Why?
Antineoplastic Agents
1
2014
2129
0.050
 Why?
Nocebo Effect
1
2022
4
0.050
 Why?
Endpoint Determination
1
2003
77
0.050
 Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2022
16
0.050
 Why?
Cyclohexanols
1
2002
12
0.050
 Why?
Vaginal Diseases
1
2002
21
0.050
 Why?
Delivery of Health Care, Integrated
2
2018
261
0.050
 Why?
Physician-Patient Relations
1
2006
548
0.050
 Why?
Information Dissemination
1
2004
218
0.050
 Why?
Sodium
1
2022
217
0.040
 Why?
Academic Medical Centers
1
2024
512
0.040
 Why?
Women's Health
1
2004
372
0.040
 Why?
Kidney Diseases
1
2005
408
0.040
 Why?
Acute Disease
1
2004
1007
0.040
 Why?
Vitamin K 1
1
2000
3
0.040
 Why?
Postmenopause
1
2003
366
0.040
 Why?
Symptom Flare Up
1
2020
39
0.040
 Why?
Medical Audit
2
2013
78
0.040
 Why?
Health Plan Implementation
1
2021
142
0.040
 Why?
Aftercare
1
2022
208
0.040
 Why?
Antifibrinolytic Agents
1
2000
51
0.040
 Why?
Liver Diseases
1
2003
315
0.040
 Why?
Patient Satisfaction
1
2004
660
0.040
 Why?
Europe
1
2020
414
0.040
 Why?
Predictive Value of Tests
1
2005
2031
0.040
 Why?
Rivaroxaban
1
2021
255
0.040
 Why?
Ibuprofen
1
1999
84
0.040
 Why?
Kidney Function Tests
1
2019
160
0.040
 Why?
Administration, Oral
1
2021
816
0.040
 Why?
Societies, Scientific
1
2019
51
0.040
 Why?
Drug Hypersensitivity
1
2000
90
0.040
 Why?
Neoplasms
1
2014
2671
0.040
 Why?
Blood Coagulation
1
2000
255
0.040
 Why?
Student Health Services
1
2018
15
0.040
 Why?
Child
2
2017
21935
0.040
 Why?
Software
1
2023
665
0.040
 Why?
Antiretroviral Therapy, Highly Active
1
1999
271
0.030
 Why?
Self Care
1
2000
380
0.030
 Why?
United States Department of Veterans Affairs
1
2022
678
0.030
 Why?
Glucose
1
2022
1020
0.030
 Why?
Homozygote
1
2017
203
0.030
 Why?
Hospitals
1
2022
691
0.030
 Why?
Felodipine
1
1996
4
0.030
 Why?
Receptors, Drug
1
1996
14
0.030
 Why?
Cost-Benefit Analysis
1
2019
591
0.030
 Why?
Public Health
1
2021
588
0.030
 Why?
Polypharmacy
1
2016
85
0.030
 Why?
Calcium Channels
1
1996
159
0.030
 Why?
Patient Discharge
1
2022
897
0.030
 Why?
Internet
1
1999
655
0.030
 Why?
Cross-Over Studies
1
1997
564
0.030
 Why?
Communication
2
2014
879
0.030
 Why?
Myocardial Ischemia
1
1996
263
0.030
 Why?
Data Interpretation, Statistical
1
1996
363
0.030
 Why?
Pain
1
1999
756
0.030
 Why?
Regression Analysis
2
2009
1024
0.030
 Why?
Clinical Decision-Making
1
2016
322
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2019
804
0.030
 Why?
Infant
2
2004
9465
0.020
 Why?
Pandemics
1
2021
1639
0.020
 Why?
Comprehension
1
2014
172
0.020
 Why?
Hemodynamics
1
1997
1113
0.020
 Why?
Adrenergic Antagonists
1
2011
7
0.020
 Why?
Renin
1
2011
35
0.020
 Why?
Educational Status
1
2014
470
0.020
 Why?
Phytotherapy
1
2011
83
0.020
 Why?
Health Planning Guidelines
1
2010
25
0.020
 Why?
Drug Utilization
1
2011
169
0.020
 Why?
Prospective Studies
3
2015
7604
0.020
 Why?
Poisson Distribution
1
2010
75
0.020
 Why?
Breast Neoplasms
1
2003
2253
0.020
 Why?
Likelihood Functions
1
2010
144
0.020
 Why?
Models, Organizational
1
2011
151
0.020
 Why?
Anti-Bacterial Agents
1
2000
1809
0.020
 Why?
Pilot Projects
1
2015
1710
0.020
 Why?
Preferred Provider Organizations
1
2009
4
0.020
 Why?
Transportation
1
2009
53
0.020
 Why?
Private Sector
1
2009
52
0.020
 Why?
Case-Control Studies
1
2016
3556
0.020
 Why?
Phenotype
1
2017
3196
0.020
 Why?
Infliximab
1
2009
111
0.020
 Why?
Interprofessional Relations
1
2011
283
0.020
 Why?
North America
1
2009
313
0.020
 Why?
Cooperative Behavior
1
2011
451
0.020
 Why?
Quality of Life
1
2019
2892
0.020
 Why?
Multivariate Analysis
1
2010
1509
0.020
 Why?
Organizational Policy
1
2006
84
0.020
 Why?
Professional Practice
1
2006
64
0.020
 Why?
Health Care Costs
1
2009
398
0.020
 Why?
Role
1
2005
31
0.010
 Why?
Time Factors
1
1996
6828
0.010
 Why?
Logistic Models
1
2010
2074
0.010
 Why?
Expert Testimony
1
2005
39
0.010
 Why?
Bone Diseases, Metabolic
1
2005
63
0.010
 Why?
Interdisciplinary Communication
1
2005
191
0.010
 Why?
Models, Economic
1
2004
58
0.010
 Why?
Diabetes Complications
1
2005
227
0.010
 Why?
Review Literature as Topic
1
2004
75
0.010
 Why?
Probability
1
2004
304
0.010
 Why?
Venlafaxine Hydrochloride
1
2002
13
0.010
 Why?
Menstruation
1
2002
43
0.010
 Why?
International Normalized Ratio
1
2000
47
0.010
 Why?
Health Maintenance Organizations
1
2000
108
0.010
 Why?
beta-Lactams
1
2000
33
0.010
 Why?
Medical Records
1
2000
177
0.010
 Why?
Hospitalization
1
2009
2199
0.010
 Why?
Sensitivity and Specificity
1
2004
1946
0.010
 Why?
Depressive Disorder
1
2002
379
0.010
 Why?
Prevalence
1
2005
2734
0.010
 Why?
Depression
1
2004
1397
0.010
 Why?
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (455) concept(s)
_
Co-Authors Expand Description
See all (54) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)